Prasugrel - CAS# 150322-43-3 lupirtine Maleate 1-6-2-4-7(8)5-3-6/h1-3

1-6-2-4-7(8)5-3-6/h1-3

Willardsen JA

Chemical Name: N-[4-(2-{[2-(4-methanesulfonamidophenyl)ethyl](methyl)amino}ethoxy)phenyl]methanesulfonamide

InChi: InChI=1S/C11H9NO2S2/c13-6-1-2-8-7(5-6)9-10(16-8)11(14)12-3-4-15-9/h1-2

19: 5003-5015

Prasugrel - CAS# 150322-43-3 lupirtine Maleate 1-6-2-4-7(8)5-3-6/h1-3Prasugrel (marketing name Effient in the US, Efient in the EU and Prasita in India) is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel was approved for use in Europe in February 2009, and is currently available in the UK. On July 10, 2009, the